Key result
Primary PTCA shows similar benefits to thrombolysis for flow, LV function, and mortality in AMI.
Why the study?
Both thrombolytic therapy and primary percutaneous transluminal coronary angioplasty restore blood flow, improve left ventricular function, and reduce mortality in acute myocardial infarction, leaving ongoing controversy over which method is more effective.
Mechanical reperfusion may benefit select AMI patients; leaves open comparative efficacy versus thrombolysis pending prospective trials.
The role of mechanical reperfusion as compared with thrombolytic therapy for the treatment of acute myocardial infarction has remained controversial since Rentrop et al.1 first reestablished perfusion in patients with myocardial infarction by dislodging the occluding coronary thrombus with a guide wire. Since then, considerable evidence has shown that thrombolytic agents are effective in restoring blood flow, improving left ventricular function, and reducing mortality from acute myocardial infarction. Primary treatment with percutaneous transluminal coronary angioplasty has been shown to have similar benefits, and controversy continues over what method is more effective.Those who favor thrombolytic therapy emphasize its advantages over . . .
No takes yet. Share an insight, caveat, or question.
Faxon et al. (1999) conducted an editorial in Acute myocardial infarction. Primary percutaneous transluminal coronary angioplasty vs. Thrombolytic therapy was evaluated on Restoring blood flow, improving left ventricular function, and reducing mortality from acute myocardial infarction. Primary percutaneous transluminal coronary angioplasty provides similar benefits to thrombolytic therapy in restoring blood flow, improving left ventricular function, and reducing mortality in AMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: